Abstract
Heparan sulfate proteoglycans (HSPGs) are primary components at the interface between virtually every eukaryotic cell and its extracellular matrix. HSPGs not only provide a storage depot for heparin-binding molecules in the cell microenvironment, but also decisively regulate their accessibility, function and mode of action. As such, they are intimately involved in modulating cell invasion and signaling loops that are critical for tumor growth, inflammation and kidney function. In a series of studies performed since the cloning of the human heparanase gene, we and others have demonstrated that heparanase, the sole heparan sulfate degrading endoglycosidase, is causally involved in cancer progression, inflammation and diabetic nephropathy and hence is a valid target for drug development. Heparanase is causally involved in inflammation and accelerates colon tumorigenesis associated with inflammatory bowel disease. Notably, heparanase stimulates macrophage activation, while macrophages induce production and activation of latent heparanase contributed by the colon epithelium, together generating a vicious cycle that powers colitis and the associated tumorigenesis. Heparanase also plays a decisive role in the pathogenesis of diabetic nephropathy, degrading heparan sulfate in the glomerular basement membrane and ultimately leading to proteinuria and kidney dysfunction. Notably, clinically relevant doses of ionizing radiation (IR) upregulate heparanase expression and thereby augment the metastatic potential of pancreatic carcinoma. Thus, combining radiotherapy with heparanase inhibition is an effective strategy to prevent tumor resistance and dissemination in IR-treated pancreatic cancer patients. Also, accumulating evidence indicate that peptides derived from human heparanase elicit a potent anti-tumor immune response, suggesting that heparanase represents a promising target antigen for immunotherapeutic approaches against a broad variety of tumours. Oligosaccharide-based compounds that inhibit heparanase enzymatic activity were developed, aiming primarily at halting tumor growth, metastasis and angiogenesis. Some of these compounds are being evaluated in clinical trials, targeting both the tumor and tumor microenvironment.
Similar content being viewed by others
Abbreviations
- ECM:
-
Extracellular matrix
- HS:
-
Heparan sulfate
- HSPGs:
-
Heparan sulfate proteoglycans
- GAG:
-
Glycosaminoglycan
- MMP:
-
Matrix metalloproteinase
- VEGF:
-
Vascular endothelial growth factor
- CAF:
-
Cancer-associated fibroblasts
- UC:
-
Ulcerative colitis
- IBD:
-
Inflammatory bowel disease
- AOM:
-
Azoxymethane
- DSS:
-
Dextran sodium sulfate
- IR:
-
Ionoizing radiation
- Egr1:
-
Early growth response 1
- CTL:
-
Cytotoxic T lymphocyte
- HAT:
-
Histone acetyltransferase
References
Vlodavsky I, Gospodarowicz D (1981) Respective roles of laminin and fibronectin in adhesion of human carcinoma and sarcoma cells. Nature 289:304–306
Vlodavsky I, Lui GM, Gospodarowicz D (1980) Morphological appearance, growth behavior and migratory activity of human tumor cells maintained on extracellular matrix versus plastic. Cell 19:607–616
Vlodavsky I (2001) Preparation of extracellular matrices produced by cultured corneal endothelial and PF-HR9 endodermal cells. Curr Protoc Cell Biol. Chapter 10:Unit 10.4
Kleinman HK, Martin GR (2005) Matrigel: basement membrane matrix with biological activity. Semin Cancer Biol 15:378–386
Xu R, Boudreau A, Bissell MJ (2009) Tissue architecture and function: dynamic reciprocity via extra- and intra-cellular matrices. Cancer Metastasis Rev 28:167–176
Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I (1988) A heparin-binding angiogenic protein–basic fibroblast growth factor–is stored within basement membrane. Am J Pathol 130:393–400
Theocharis AD, Skandalis SS, Tzanakakis GN, Karamanos NK (2010) Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J 277:3904–3923
Iozzo RV, San Antonio JD (2001) Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest 108:349–355
Kjellen L, Lindahl U (1991) Proteoglycans: structures and interactions. Annu Rev Biochem 60:443–475
Bernfield M, Gotte M, Park PW et al (1999) Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68:729–777
Capila I, Linhardt RJ (2002) Heparin-protein interactions. Angew Chem Int Ed Engl 41:391–412
Lindahl U, Li JP (2009) Interactions between heparan sulfate and proteins-design and functional implications. Int Rev Cell Mol Biol 276:105–159
Ogren S, Lindahl U (1975) Cleavage of macromolecular heparin by an enzyme from mouse mastocytoma. J Biol Chem 250:2690–2697
Thunberg L, Backstrom G, Wasteson A, Robinson HC, Ogren S, Lindahl U (1982) Enzymatic depolymerization of heparin-related polysaccharides. Substrate specificities of mouse mastocytoma and human platelet endo-beta-D-glucuronidases. J Biol Chem 257:10278–10282
Parish CR, Freeman C, Hulett MD (2001) Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 1471:M99–M108
Lerner I, Hermano E, Zcharia E et al (2011) Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J Clin Invest 121:1709–1721
Li RW, Freeman C, Yu D et al (2008) Dramatic regulation of heparanase activity and angiogenesis gene expression in synovium from patients with rheumatoid arthritis. Arthritis Rheum 58:1590–1600
van den Hoven MJ, Rops AL, Bakker MA et al (2006) Increased expression of heparanase in overt diabetic nephropathy. Kidney Int 70:2100–2108
Lindahl U (1990) Biosynthesis of heparin. Biochem Soc Trans 18:803–805
Kreuger J, Spillmann D, Li JP, Lindahl U (2006) Interactions between heparan sulfate and proteins: the concept of specificity. J Cell Biol 174:323–327
Ledin J, Staatz W, Li JP et al (2004) Heparan sulfate structure in mice with genetically modified heparan sulfate production. J Biol Chem 279:42732–42741
Gray E, Mulloy B, Barrowcliffe TW (2008) Heparin and low-molecular-weight heparin. Thromb Haemost 99:807–818
Lindahl U (2007) Heparan sulfate-protein interactions–a concept for drug design? Thromb Haemost 98:109–115
Fransson LA, Belting M, Cheng F, Jonsson M, Mani K, Sandgren S (2004) Novel aspects of glypican glycobiology. Cell Mol Life Sci 61:1016–1024
Cole GJ, Halfter W (1996) Agrin: an extracellular matrix heparan sulfate proteoglycan involved in cell interactions and synaptogenesis. Perspect Dev Neurobiol 3:359–371
Iozzo RV (1998) Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 67:609–652
Kramer KL, Yost HJ (2003) Heparan sulfate core proteins in cell-cell signaling. Annu Rev Genet 37:461–484
Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U (2002) Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2:521–528
Simons M, Horowitz A (2001) Syndecan-4-mediated signalling. Cell Signal 13:855–862
Timpl R, Brown JC (1996) Supramolecular assembly of basement membranes. Bioessays 18:123–132
Hacker U, Nybakken K, Perrimon N (2005) Heparan sulphate proteoglycans: the sweet side of development. NatRev Mol Cell Biol 6:530–541
Sanderson RD (2001) Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Devel Biol 12:89–98
Timar J, Lapis K, Dudas J, Sebestyen A, Kopper L, Kovalszky I (2002) Proteoglycans and tumor progression: Janus-faced molecules with contradictory functions in cancer. Semin Cancer Biol 12:173–186
Belting M (2003) Heparan sulfate proteoglycan as a plasma membrane carrier. Trends Biochem Sci 28:145–151
Bashkin P, Doctrow S, Klagsbrun M, Svahn CM, Folkman J, Vlodavsky I (1989) Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 28:1737–1743
Patel VN, Knox SM, Likar KM et al (2007) Heparanase cleavage of perlecan heparan sulfate modulates FGF10 activity during ex vivo submandibular gland branching morphogenesis. Development 134:4177–4186
Vlodavsky I, Bar-Shavit R, Ishai-Michaeli R, Bashkin P, Fuks Z (1991) Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism? Trends Biochem Sci 16:268–271
Vlodavsky I, Miao HQ, Medalion B, Danagher P, Ron D (1996) Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis Rev 15:177–186
Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, Vlodavsky I (2010) Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J 277:3890–3903
Ilan N, Elkin M, Vlodavsky I (2006) Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 38:2018–2039
Levy-Adam F, Feld S, Cohen-Kaplan V et al (2010) Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity. J Biol Chem 285:28010–28019
McKenzie E, Tyson K, Stamps A et al (2000) Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member. Biochem Biophys Res Commun 276:1170–1177
Vlodavsky I, Eldor A, Haimovitz-Friedman A et al (1992) Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 12:112–127
Elkin M, Ilan N, Ishai-Michaeli R et al (2001) Heparanase as mediator of angiogenesis: mode of action. FASEB J 15:1661–1663
Levy-Adam F, Miao HQ, Heinrikson RL, Vlodavsky I, Ilan N (2003) Heterodimer formation is essential for heparanase enzymatic activity. Biochem Biophys Res Commun 308:885–891
McKenzie E, Young K, Hircock M et al (2003) Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells. Biochem J 373:423–435
Nardella C, Lahm A, Pallaoro M, Brunetti M, Vannini A, Steinkuhler C (2004) Mechanism of activation of human heparanase investigated by protein engineering. Biochemistry 43:1862–1873
Fux L, Ilan N, Sanderson RD, Vlodavsky I (2009) Heparanase: busy at the cell surface. Trends Biochem Sci 34:511–519
Hulett MD, Hornby JR, Ohms SJ et al (2000) Identification of active-site residues of the pro-metastatic endoglycosidase heparanase. Biochemistry 39:15659–15667
Abboud-Jarrous G, Rangini-Guetta Z, Aingorn H et al (2005) Site-directed mutagenesis, proteolytic cleavage, and activation of human proheparanase. J Biol Chem 280:13568–13575
Abboud-Jarrous G, Atzmon R, Peretz T et al (2008) Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J Biol Chem 283:18167–18176
Nakajima M, Irimura T, DiFerrante D, DiFerrante N, Nicolson GL (1983) Heparan sulfate degradation: relation to tumor invasion and metastatic properties of Mouse B 16 Melanoma sublines. Science 220:611–613
Vlodavsky I, Fuks Z, Bar-Ner M, Ariav Y, Schirrmacher V (1983) Lymphoma cells mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relation to tumor cell metastasis. Cancer Res 43:2704–2711
Cohen I, Pappo O, Elkin M et al (2006) Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer 118:1609–1617
Lerner I, Baraz L, Pikarsky E et al (2008) Function of heparanase in prostate tumorigenesis: potential for therapy. Clin Cancer Res 14:668–676
Edovitsky E, Elkin M, Zcharia E, Peretz T, Vlodavsky I (2004) Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst 96:1219–1230
Vreys V, David G (2007) Mammalian heparanase: what is the message? J Cell Mol Med 11:427–452
Shafat I, Ben-Arush MW, Issakov J, Meller I, Naroditsky I, Tortoteto M, Cassinelli G, Lanzi C, Pisano C, Ilan N, Vlodavsky I, Zunino F (2011) J cell mol med (PMID: 21029368)
Vlodavsky I, Ilan N, Naggi A, Casu B (2007) Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des 13:2057–2073
Casu B, Guerrini M, Guglieri S et al (2004) Undersulfated and glycol-split heparins endowed with antiangiogenic activity. J Med Chem 47:838–848
Ferro V, Hammond E, Fairweather JK (2004) The development of inhibitors of heparanase, a key enzyme involved in tumour metastasis, angiogenesis and inflammation. Mini Rev Med Chem 4:693–702
McKenzie EA (2007) Heparanase: a target for drug discovery in cancer and inflammation. Br J Pharmacol 151:1–14
Miao HQ, Liu H, Navarro E, Kussie P, Zhu Z (2006) Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem 13:2101–2111
Doweck I, Kaplan-Cohen V, Naroditsky I, Sabo E, Ilan N, Vlodavsky I (2006) Neoplasia 8:1055–1061
El-Assal ON, Yamanoi A, Ono T, Kohno H, Nagasue N (2001) Clin Cancer Res 7(5):1299–1305
Maxhimer JB, Quiros RM, Stewart R, Dowlatshahi K, Gattuso P, Fan M, Prinz RA, Xu X (2002) Surgery 132:326–333
Nagler R, Ben-Izhak O, Cohen-Kaplan V, Shafat I, Vlodavsky I, Akrish S, Ilan N (2007) Cancer 110:2732–2739
Tang W, Nakamura Y, Tsujimoto M, Sato M, Wang X, Kurozumi K, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K (2002) Mod Pathol 15:593–598
Barash U, Cohen-Kaplan V, Arvatz G et al (2010) A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics. FASEB J 24:1239–1248
Doviner V, Maly B, Kaplan V et al (2006) Spatial and temporal heparanase expression in colon mucosa throughout the adenoma-carcinoma sequence. Mod Pathol 19:878–888
Yang Y, Macleod V, Bendre M et al (2005) Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood 105:1303–1309
Zetser A, Bashenko Y, Miao H-Q, Vlodavsky I, Ilan N (2003) Heparanase affects adhesive and tumorigenic potential of human glioma cells. Cancer Res 63:7733–7741
Vlodavsky I, Korner G, Ishai-Michaeli R, Bashkin P, Bar-Shavit R, Fuks Z (1990) Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev 9:203–226
Witz IP (2008) Tumor-microenvironment interactions: dangerous liaisons. Adv Cancer Res 100:203–229
Ruoslahti E (1996) How cancer spreads. Sci Am 275:72–77
Liotta LA, Kohn EC (2001) The microenvironment of the tumour-host interface. Nature 411:375–379
Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141:52–67
Mason SD, Joyce JA (2011) Proteolytic networks in cancer. Trends Cell Biol 21:228–237
Stupack DG, Cheresh DA (2004) Integrins and angiogenesis. Curr Top Dev Biol 64:207–238
Noel A, Jost M, Maquoi E (2008) Matrix metalloproteinases at cancer tumor-host interface. Sem Cell Dev Biol 19:52–60
Van Damme J, Struyf S, Opdenakker G (2004) Chemokine-protease interactions in cancer. Semin Cancer Biol 14:201–208
Gocheva V, Joyce JA (2007) Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 6:60–64
Lankelma JM, Voorend DM, Barwari T et al (2010) Cathepsin L, target in cancer treatment? Life Sci 86:225–233
Turk B, Turk D, Turk V (2000) Lysosomal cysteine proteases: more than scavengers. Biochim Biophys Acta 1477:98–111
Bix G, Iozzo RV (2005) Matrix revolutions: “tails” of basement-membrane components with angiostatic functions. Trends Cell Biol 15:52–60
Purushothaman A, Chen L, Yang Y, Sanderson RD (2008) Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem 283:32628–32636
Zcharia E, Jia J, Zhang X et al (2009) Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS ONE 4:e5181
Chen L, Sanderson RD (2009) Heparanase regulates levels of syndecan-1 in the nucleus. PLoS ONE 4(3):e4947
Paget S (1889) The distribution of a secondary growths in cancer of the breast. Lancet 133:571–583
Talmadge JE, Fidler IJ (2010) AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 70:5649–5669
Nicolson GL (1988) Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev 7:143–188
Kaplan RN, Psaila B, Lyden D (2006) Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond. Cancer Metastasis Rev 25:521–529
Kaplan RN, Rafii S, Lyden D (2006) Preparing the “soil”: the premetastatic niche. Cancer Res 66:11089–11093
Kaplan RN, Riba RD, Zacharoulis S et al (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438:820–827
Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391–400
Franco OE, Shaw AK, Strand DW, Hayward SW (2010) Cancer associated fibroblasts in cancer pathogenesis. Sem Cell Dev Biol 21:33–39
Shimoda M, Mellody KT, Orimo A (2010) Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Sem cell Dev Biol 221:19–25
Bhowmick NA, Chytil A, Plieth D et al (2004) TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303:848–851
Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432:332–337
Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6:392–401
Erez N, Truitt M, Olson P, Arron ST, Hanahan D (2010) Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 17:135–147
Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883–899
Mantovani A, Sica A (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Cur Opin Immunol 22:231–237
Condeelis J, Pollard JW (2006) Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124:263–266
Dirkx AE, Oude Egbrink MG, Wagstaff J, Griffioen AW (2006) Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol 80:1183–1196
Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4:71–78
Edovitsky E, Lerner I, Zcharia E, Peretz T, Vlodavsky I, Elkin M (2006) Role of endothelial heparanase in delayed-type hypersensitivity. Blood 107:3609–3616
Waterman M, Ben-Izhak O, Eliakim R, Groisman G, Vlodavsky I, Ilan N (2007) Heparanase upregulation by colonic epithelium in inflammatory bowel disease. Mod Pathol 20:8–14
Clevers H (2006) Colon cancer–understanding how NSAIDs work. N Engl J Med 354:761–763
Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749–759
Greten FR, Eckmann L, Greten TF et al (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285–296
Popivanova BK, Kitamura K, Wu Y et al (2008) Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 118:560–570
Okayasu I, Ohkusa T, Kajiura K, Kanno J, Sakamoto S (1996) Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut 39:87–92
Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441:431–436
Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9:798–809
Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98:694–702
Zcharia E, Metzger S, Chajek-ShaulL T et al (2004) Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. FASEB J 18:252–263
Mahida YR (2000) The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis 6:21–33
Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK (2008) Role of cytokines in inflammatory bowel disease. World J Gastroenterol 14:4280–4288
Elson CO, Sartor RB, Tennyson GS, Riddell RH (1995) Experimental models of inflammatory bowel disease. Gastroenterology 109:1344–1367
Krieglstein CF, Cerwinka WH, Sprague AG et al (2002) Collagen-binding integrin alpha1beta1 regulates intestinal inflammation in experimental colitis. J Clin Invest 110:1773–1782
Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295:2387–2392
Brunn GJ, Bungum MK, Johnson GB, Platt JL (2005) Conditional signaling by Toll-like receptor 4. FASEB J 19:872–874
Fukata M, Chen A, Vamadevan AS et al (2007) Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 133:1869–1881
Fukata M, Hernandez Y, Conduah D et al (2009) Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm Bowel Dis 15:997–1006
Kumar V, Abbas A, Fausto N, (eds) (2005) Pathologic basis of disease: Elsevier Saunders
de Mestre AM, Rao S, Hornby JR, Soe-Htwe T, Khachigian LM, Hulett MD (2005) Early Growth Response gene 1 (EGR1) regulates heparanase gene transcription in tumor cells. J Biol Chem 280:35136–35147
Subbaramaiah K, Yoshimatsu K, Scherl E et al (2004) Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease. Evidence for involvement of the transcription factor Egr-1. J Biol Chem 279:12647–12658
Fiebiger E, Maehr R, Villadangos J et al (2002) Invariant chain controls the activity of extracellular cathepsin L. J Exp Med 196:1263–1269
Bouma G, Strober W (2003) The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3:521–533
Borja-Cacho D, Jensen EH, Saluja AK, Buchsbaum DJ, Vickers SM (2008) Molecular targeted therapies for pancreatic cancer. Am J Surg 196:430–441
Raimondi S, Maisonneuve P, Lowenfels AB (2009) Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 6:699–708
Shaib YH, Davila JA, El-Serag HB (2006) The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment Pharmacol Ther 24:87–94
Muller MW, Friess H, Koninger J et al (2008) Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas. Am J Surg 195:221–228
Network NCC (2008) NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma. v.1
Cohen SJ, Dobelbower R Jr, Lipsitz S et al (2005) A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys 62:1345–1350
Neoptolemos JP, Stocken DD, Friess H et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200–1210
Camphausen K, Moses MA, Beecken W-D, Khan MK, Folkman J, O’Reilly MS (2001) Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res 61:2207–2211
Kaliski A, Maggiorella L, Cengel KA et al (2005) Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion. Mol Cancer Ther 4:1717–1728
Madani I, De Neve W, Mareel M (2008) Does ionizing radiation stimulate cancer invasion and metastasis? Bull Cancer 95:292–300
Ohuchida K, Mizumoto K, Murakami M et al (2004) Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res 64:3215–3222
Park CM, Park MJ, Kwak HJ et al (2006) Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res 66:8511–8519
Qian L-W, Mizumoto K, Urashima T et al (2002) Radiation-induced increase in invasive potential of human pancreatic cancer cells and its blockade by a matrix metalloproteinase inhibitor, CGS27023. Clin Cancer Res 8:1223–1227
Wild-Bode C, Weller M, Rimner A, Dichgans J, Wick W (2001) Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res 61:2744–2750
Meirovitz A, Hermano E, Lerner I et al (2011) Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma. Cancer Res 71:2772–2780
Koliopanos A, Friess H, Kleeff J, Shi X, Liao Q, Pecker I, Vlodavsky I, Zimmermann A, Buchler MW (2001) Cancer Res 61:4655–4659
Quiros RM, Rao G, Plate J et al (2006) Elevated serum heparanase-1 levels in patients with pancreatic carcinoma are associated with poor survival. Cancer 106:532–540
Rohloff J, Zinke J, Schoppmeyer K, Tannapfel A, Witzigmann H, Mossner J, Wittekind C, Caca K (2002) Br J Cancer 86:1270–1275
Hoffmann AC, Mori R, Vallbohmer D et al (2008) High expression of heparanase is significantly associated with dedifferentiation and lymph node metastasis in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA and via HIF1a to HB-EGF and bFGF. J Gastrointest Surg 12:1674–1681
de Mestre AM, Khachigian LM, Santiago FS, Staykova MA, Hulett MD (2003) Regulation of inducible heparanase gene transcription in activated T cells by early growth response 1. J Biol Chem 278:50377–50385
de Mestre AM, Staykova MA, Hornby JR, Willenborg DO, Hulett MD (2007) Expression of the heparan sulfate-degrading enzyme heparanase is induced in infiltrating CD4+ T cells in experimental autoimmune encephalomyelitis and regulated at the level of transcription by early growth response gene 1. J Leukoc Biol 82:1289–1300
Srinivasan R, Mager GM, Ward RM, Mayer J, Svaren J (2006) NAB2 represses transcription by interacting with the CHD4 subunit of the nucleosome remodeling and deacetylase (NuRD) complex. J Biol Chem 281:15129–15137
Casu B, Guerrini M, Torri G (2004) Structural and conformational aspects of the anticoagulant and anti-thrombotic activity of heparin and dermatan sulfate. Curr Pharm Des 10:939–949
Casu B, Vlodavsky I, Sanderson RD (2008) Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb 36:195–203
Naggi A, Casu B, Perez M et al (2005) Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem 280:12103–12113
Chung SI, Seong J, Park YN, Kim WW, Oh HJ, Han KH. Identification of proteins indicating radiation-induced hepatic toxicity in cirrhotic rats. J Rsd Res 51:643–650
Iriyama S, Matsunaga Y, Takahashi K, Matsuzaki K, Kumagai N, Amano S (2011) Activation of heparanase by ultraviolet B irradiation leads to functional loss of basement membrane at the dermal-epidermal junction in human skin. Arch Dermatol Res 303:253–261
Chen T, Tang XD, Wan Y et al (2008) HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy. Neoplasia 10:977–986
Tang W, Nakamura Y, Tsujimoto M et al (2002) Heparanase: a key enzyme in invasion and metastasis of gastric carcinoma. Mod Pathol 15:593–598
Tang XD, Liang GP, Li C et al (2010) Cytotoxic T lymphocyte epitopes from human heparanase can elicit a potent anti-tumor immune response in mice. Cancer Immunol Immunother 59:1041–1047
Wang GZ, Tang XD, Lu MH, et al (2011) Multiple antigenic peptides of human heparanase elicit a much more potent immune response against tumors. Canc Prev Res (PMID: 21505182)
Beckhove P, Feuerer M, Dolenc M et al (2004) Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J Clin Invest 114:67–76
Feuerer M, Beckhove P, Garbi N et al (2003) Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med 9:1151–1157
Khazaie K, Prifti S, Beckhove P et al (1994) Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection. Proc Natl Acad Sci USA 91:7430–7434
Schirrmacher V, Feuerer M, Fournier P, Ahlert T, Umansky V, Beckhove P (2003) T-cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity. Trends Mol Med 9:526–534
Bai L, Beckhove P, Feuerer M et al (2003) Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo. Int J Cancer 103:73–83
Schmitz-Winnenthal FH, Volk C, Z’Graggen K et al (2005) High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res 65:10079–10087
Wagner P, Koch M, Nummer D et al (2008) Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer. Ann Surg Oncol 15:2310–2317
Schuetz F, Ehlert K, Ge Y et al (2008) Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study. Cancer Immunol Immunother 58:887–900
Sommerfeldt N, Beckhove P, Ge Y et al (2006) Heparanase: a new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes. Cancer Res 66:7716–77123
Bonertz A, Weitz J, Pietsch DH et al (2009) Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 119:3311–3321
Schuetz F, Ehlert K, Ge Y et al (2009) Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study. Cancer Immunol Immunother 58:887–900
Levy-Adam F, Ilan N, Vlodavsky I (2010) Tumorigenic and adhesive properties of heparanase. Semin Cancer Biol 20:153–160
Levy-Adam F, Feld S, Suss-Toby E, Vlodavsky I, Ilan N (2008) Heparanase facilitates cell adhesion and spreading by clustering of cell surface heparan sulfate proteoglycans. PLoS ONE 3:e2319
Kim MY, Oskarsson T, Acharyya S et al (2009) Tumor self-seeding by circulating cancer cells. Cell 139:1315–1326
Leung CT, Brugge JS (2009) Tumor self-seeding: bidirectional flow of tumor cells. Cell 139:1226–1228
Joyce JA, Freeman C, Meyer-Morse N, Parish CR, Hanahan D (2005) A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene 24:4037–4051
Friedmann Y, Vlodavsky I, Aingorn H, Aviv A, Peretz T, Pecker I, Pappo O (2000) Am J Pathol 157(4):1167–1175
Brun R, Naroditsky I, Waterman M et al (2009) Heparanase expression by Barrett’s epithelium and during esophageal carcinoma progression. Mod Pathol 22:1548–1554
Cohen-Kaplan V, Naroditsky I, Zetser A, Ilan N, Vlodavsky I, Doweck I (2008) Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer 123:2566–2573
Buczek-Thomas JA, Hsia E, Rich CB, Foster JA, Nugent MA (2008) Inhibition of histone acetyltransferase by glycosaminoglycans. J Cell Biochem 105:108–120
Kovalszky I, Dudas J, Olah-Nagy J et al (1998) Inhibition of DNA topoisomerase I activity by heparan sulfate and modulation by basic fibroblast growth factor. Mol Cell Biochem 183:11–23
Ohkawa T, Naomoto Y, Takaoka M et al (2004) Localization of heparanase in esophageal cancer cells: respective roles in prognosis and differentiation. Lab Invest 84:1289–1304
Schubert SY, Ilan N, Shushy M, Ben-Izhak O, Vlodavsky I, Goldshmidt O (2004) Human heparanase nuclear localization and enzymatic activity. Lab Invest 84:535–544
Kobayashi M, Naomoto Y, Nobuhisa T et al (2006) Heparanase regulates esophageal keratinocyte differentiation through nuclear translocation and heparan sulfate cleavage. Differentiation 74:235–243
Purushothaman A, Hurst DR, Pisano C, Mizumoto S, Sugahara K, Sanderson RD (2011) Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. J Biol Chem PMID: 21757697
Szymczak M, Kuzniar J, Klinger M (2010) The role of heparanase in diseases of the glomeruli. Arch Immunol Ther Exp 58:45–56
van den Hoven MJ, Rops AL, Vlodavsky I, Levidiotis V, Berden JH, van der Vlag J (2007) Heparanase in glomerular diseases. Kidney Int 72:543–548
Levidiotis V, Freeman C, Tikellis C, Cooper ME, Power DA (2004) Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis. J Am Soc Nephrol 15:68–78
Levidiotis V, Kanellis J, Ierino FL, Power DA (2001) Increased expression of heparanase in puromycin aminonucleoside nephrosis. Kidney Int 60:1287–1296
Levidiotis V, Freeman C, Tikellis C, Cooper ME, Power DA (2005) Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease. Nephrology 10:167–173
Ritchie JP, Ramani VC, Ren Y et al (2011) SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res 17:1382–1393
Higgins WJ, Fox DM, Kowalski PS, Nielsen JE, Worrall DM (2010) Heparin enhances serpin inhibition of the cysteine protease cathepsin L. J Biol Chem 285:3722–3729
Arvatz G, Shafat I, Levy-Adam F, Ilan N, Vlodavsky I (2011) The heparanase system and tumor metastasis: is heparanase the seed and soil? Cancer Metastasis Rev 30:253–268
Dredge K, Hammond E, Handley P et al (2011) PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br J Cancer 104:635–642
Zhang L, Sullivan PS, Goodman JC, Gunaratne PH, Marchetti D (2011) MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. Cancer Res 71:645–654
Gohji K, Hirano H, Okamoto M, Kitazawa S, Toyoshima M, Dong J, Katsuoka Y, Nakajima M (2001) Int J Cancer 95:295–301
Gohji K, Okamoto M, Kitazawa S, Toyoshima M, Dong J, Katsuoka Y, Nakajima M (2001) J Urol 166:1286–1290
Shinyo Y, Kodama J, Hongo A, Yoshinouchi M, Hiramatsu Y (2003) Ann Oncol 14:1505–1510
Nobuhisa T, Naomoto Y, Ohkawa T, Takaoka M, Ono R, Murata T, Gunduz M, Shirakawa Y, Yamatsuji T, Haisa M, Matsuoka J, Tsujigiwa H, Nagatsuka H, Nakajima M, Tanaka N (2005) J Cancer Res Clin Oncol 131:229–237
Sato T, Yamaguchi A, Goi T, Hirono Y, Takeuchi K, Katayama K, Matsukawa S (2004) J Surg Oncol 87:174–181
Watanabe M, Aoki Y, Kase H, Tanaka K (2003) Gynecol Obstet Invest 56:77–82
Endo K, Maejara U, Baba H, Tokunaga E, Koga T, Ikeda Y, Toh Y, Kohnoe S, Okamura T, Nakajima M, Sugimachi K (2001) Anticancer Res 21:3365–3369
Takaoka M, Naomoto Y, Ohkawa T, Uetsuka H, Shirakawa Y, Uno F, Fujiwara T, Gunduz M, Nagatsuka H, Nakajima M, Tanaka N, Haisa M (2003) Lab Invest 83:613–622
Takahashi H, Ebihara S, Okazaki T, Suzuki S, Asada M, Kubo H, Sasaki H (2004) Lung Canc (Amsterdam, Netherlands) 45: 207–214
Cohen E, Doweck I, Naroditsky I, Ben-Izhak O, Kremer R, Best LA, Vlodavsky I, Ilan N (2008) Cancer 113:1004–1011
Kelly T, Miao H-Q, Yang Y, Navarro E, Kussie P, Huang Y, MacLeod V, Casciano J, Joseph L, Zhan F, Zangari M, Barlogie B, Shaughnessy J, Sanderson RD (2003) Cancer Res 63:8749–8756
Bar-Sela G, Kaplan-Cohen V, Ilan N, Vlodavsky I, Ben-Izhak O (2006) Histopathology 49:188–193
Zheng LD, Tong QS, Tang ST, Du ZY, Liu Y, Jiang GS, Cai JB (2009) World J Pediatr 5:206–210
Kim AW, Xu X, Hollinger EF, Gattuso P, Godellas CV, Prinz RA (2002) J Gastrointest Surg 6:167–172
Mikami S, Oya M, Shimoda M, Mizuno R, Ishida M, Kosaka T, Mukai M, Nakajima M, Okada Y (2008) Clin Cancer Res 14:6055–6061
Ben-Izhak O, Kaplan-Cohen V, Ilan N, Gan S, Vlodavsky I, Nagler R (2006) Neoplasia 8:879–884
Acknowledgements
We thank Prof. Benito Casu (‘Ronzoni’ Institute, Milan, Italy) and Prof. Ralph Sanderson (University of Alabama at Birmingham) for their continuous support and active collaboration. This work was supported by National Institutes of Health (NIH) grants CA106456 (IV) and CA138535 (RDS), the Israel Science Foundation (549/06); the Ministry of Science & Technology of the State of Israel and the German Cancer Research Center (DKFZ), the Juvenile Diabetes Research Foundation (JDRF 1-2006-695 and 38-2009-635) and by a research contract from Sigma-Tau Research Switzerland S.A. I. Vlodavsky is a Research Professor of the ICRF. We gratefully acknowledge the contribution, motivation and assistance of the research teams in the Hadassah-Hebrew University Medical Center (Jerusalem, Israel) and the Cancer and Vascular Biology Research Center of the Rappaport Faculty of Medicine (Technion, Haifa).
Conflict of Interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vlodavsky, I., Beckhove, P., Lerner, I. et al. Significance of Heparanase in Cancer and Inflammation. Cancer Microenvironment 5, 115–132 (2012). https://doi.org/10.1007/s12307-011-0082-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12307-011-0082-7